(MENAFN- GlobeNewsWire - Nasdaq) Advances in genomic research, AI-based analytics, and external partnerships in drug development are driving the global market to grow rapidly.Austin, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Personalized Medicine Outsourcing Market Size & Growth Analysis:
According to SNS Insider, the Personalized Medicine Outsourcing Market was valued at USD 109.88 billion in 2024. The market is expected to grow to USD 281.72 billion by 2032, at a CAGR of 12.54 percent from 2025 to 2032. The market is being strengthened by the increasing prevalence of chronic diseases and rare diseases globally, the increasing use of companion diagnostics, and the incorporation of artificial intelligence.
In the US, the market was worth USD 30.61 billion in 2024 and is projected to reach USD 77.07 billion in 2032. North America maintains its leadership in this sector due to the country's strong healthcare infrastructure and high R&D investment.
Get free Sample Report of Personalized Medicine Outsourcing Market:
The demand for personalized treatments is increasing in the healthcare sector. Biopharma companies are entering into strategic partnerships with contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and diagnostic service providers for research and development. This approach reduces research time and saves costs.
Major Players Analysis Listed in the Personalized Medicine Outsourcing Market Report are
Aurigene Pharmaceutical Services Syngene Syneos Health Infosys Parexel Catalent ICON HCL Technologies Lonza Thermo Fisher Scientific LabCorp Charles River Laboratories WuXi AppTec PRA Health Sciences PPD IQVIA Recipharm AB Samsung Biologics Fujifilm Diosynth Eurofins Scientific Bio‐Rad Laboratories Frontage Laboratories Svar Life Science Sino Biological Almac Group SCTbio Ology Bioservices BioSpring
Segmentation Analysis:
By Phase
The clinical phase segment accounted for the largest share of the market in 2024, with a 66.41%, due to the increasing number of precision medicine clinical trials, growing patient recruitment across oncology, rare diseases, and chronic illnesses. The preclinical segment is anticipated to grow at the fastest rate during the forecast period due to a surge in investment for early-stage drug discovery for personalized therapies.
By Application
The oncology segment held the largest personalized medicine outsourcing market share in 2024 with 55.2%, owing to the high occurrence of different cancers and associated benefits of targeted therapies. The rare diseases segment is expected to grow significantly in the forecast years, owing to the increasing emphasis on developing orphan drugs and the growing implementation of genomics and personalized treatment plans.
By Service
Due to the growing requirement for scalable production of custom-made therapeutics, particularly cell and gene therapeutics, the contract manufacturing segment occupied the largest value share of the personalized medicine outsourcing market in 2024. During the forecast years, the contract development segment is expected to experience the highest growth, as increasing personalized medicine development has become increasingly complex, and requires highly specialized capabilities.
By Type
In 2024, the inhibitor pharmaceuticals segment dominated the personalized medicine outsourcing market because of their widespread use in targeted therapies for chronic and life-threatening ailments such cancer, autoimmune diseases, and cardiovascular disorders. The cell & gene therapy segment is anticipated to register fastest growth over the forecast period, owing to significant technological breakthroughs, increasing approvals from the FDA and EMA, and growing investment by pharmaceutical giants into this area.
By Region
Due to the established healthcare infrastructure, vigorous regulatory frameworks, and high health expenditure, the global personalized medicine outsourcing market is primarily driven by North America, with a 36.6% market share in 2024.
Asia Pacific is projected to be the fastest-growing region in the personalized medicine outsourcing market trend due to an increase in healthcare expenditure, the increasing pharmaceutical manufacturing activities, and the increasing number of clinical trial activities.
Buy the Personalized Medicine Outsourcing Market Report Now:
Recent News:
July 2024 – Aurigene Pharmaceutical Services, a contract research, development, and manufacturing organization (CRO/CDMO) based in India, said that it has signed an agreement to offer discovery services in cell therapy to Edity Therapeutics, an Israeli-headquartered biotechnology firm. July 2024 – Syngene International, a contracted research, development, and manufacturing organization (CRDMO), launched a novel protein manufacturing platform for rapid and efficient protein production. The platform combines a cell line and transposon-based technology licensed from ExcellGene, a Swiss company with expertise in developing mammalian cell lines.
Exclusive Sections of the Report (The USPs):
PERSONALIZED MEDICINE ADOPTION METRICS – helps you evaluate adoption rates across therapy types, healthcare settings, and regions, providing insight into market maturity and potential outsourcing hotspots. PRECISION DIAGNOSTICS OUTSOURCING INDEX – helps you understand growth trends in companion diagnostics, genomic profiling, and biomarker discovery services, highlighting innovation-driven outsourcing opportunities. CLINICAL TRIAL OUTSOURCING ANALYTICS – helps you assess regional trends, trial volumes, and time-to-market advantages achieved through outsourcing personalized drug development. R&D AND HEALTHCARE SPENDING BENCHMARKS – helps you identify how public and private stakeholders allocate budgets for personalized medicine and gauge outsourcing spend as a share of total R&D investment. REGULATORY AND REIMBURSEMENT FRAMEWORKS – helps you analyze FDA and EMA initiatives, evolving reimbursement models, and IP/data compliance trends influencing outsourcing preferences globally. INNOVATION & COLLABORATION INDEX – helps you track strategic partnerships between CROs, CDMOs, and healthcare institutions driving precision medicine scalability and long-term growth.
Personalized Medicine Outsourcing Market Report Scope
| Report Attributes | Details |
| Market Size in 2024 | USD 109.88 Billion |
| Market Size by 2032 | USD 281.72 Billion |
| CAGR | CAGR of 12.54% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Key Segments | . By Product (Clinical, Preclinical)
. By Application (Oncology, Rare Diseases, Infectious Diseases, Others)
. By Service (Contract Manufacturing, Contract Development)
. By Type (Inhibitor Drugs, Monoclonal Antibodies, Cell & Gene Therapy, Others)
. By End Use (Pharmaceutical Companies, Biotechnology Companies, Others) |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us:
Rohan Jadhav - Principal Consultant
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email:...
Comments
No comment